From public research to business innovation!

INDEME: A targeted approach for vitiligo

Domain Health and wellbeing

Technology Metaomic

Applications

Therapy dedicated to depigmentation disorders such as VITILIGO

  • Most common depigmenting disorder (0.5-1% of the world population)
  • Stigma and major negative impact on patients’ quality of life
  • No cure nor way of restricting the spread of the disease reported so far

Decription

Identification of a core molecule X1 involved in melanocytes loss

  • Ex vivo analysis
    • Higher X1 expression in vitiligo patients’ skin and sera compared to healthy subjects
    • Vitiligo patients:  Positive correlation between X1 level and the body surface area involved
  • POC in vitro:
    • Inhibitors targeting X1 prevent melanocyte loss in an in vitro model

Benefits

  • Development of the first targeted therapy dedicated to vitiligo, an inflammatory skin disorder with high unmet medical needs
  • Near-orphan status for drug development

Inventors

Katia BONIFACE

Julien SENESCHAL

Biotherapy of genetic diseases, inflammatory disorders and cancer (BMGIC, U 1035)

IP

This technology is protected by a patent application

Contact

Jean-Luc Chagnaud

%6a%6c%2e%63%68%61%67%6e%61%75%64%40%61%73%74%2d%69%6e%6e%6f%76%61%74%69%6f%6e%73%2e%63%6f%6d